Introduction to cortical pathology in multiple sclerosis (MS)
Large-scale gene expression profiling provides an unbiased search for candidate genes and pathways altered in MS. Gene expression profiling studies to date have been predicated on the traditional model of MS as a disease in which the peripheral immune system targets the white matter. Studies have compared both peripheral blood mononuclear cells and immune cell subsets from MS patients, focusing on patients with relapsing-remitting disease. 9, 10 The majority of autopsy studies have looked at the white matter in MS brains. Recent thinking in MS, however, has been directed toward determining the cause of neurological dysfunction in late-stage progressive MS, 11 in which systemic immune responses may be less important and current anti-inflammatory drugs show little benefit. It is in this progressive phase that cortical pathology may be more associated with neurological dysfunction. Examining the genetic substrate of cortical pathology in MS brains should therefore provide a unique opportunity to determine the cause of this neurological dysfunction. Gene expression changes in cortical tissues from MS patients are emerging and Table 1 summarizes major findings of these studies to date.
Gene expression studies in normal appearing cortex
Existing studies looking at MS normal appearing white matter (NAWM) have shown that there are pathological and gene changes in MS NAWM compared to control white matter tissues. 1, 9, 10, 12 Extending the same thinking to the gray matter, gene changes have been studied in normal appearing motor cortex tissue isolated from MS brains and healthy controls. 13 In line with the demonstration of similar levels of myelin immunostaining, mRNA of myelin genes were not significantly different between MS patients and controls. The results do, however, identify a significant decrease in genes belonging to two broad biological categories: oxidative phosphorylation and GABAergic neurotransmission.
First, in the category of oxidative phosphorylation, a significant reduction in mRNA of nuclear-encoded mitochondrial genes was observed, translating into decreased protein expression. This decrease in both mRNA and protein expression was accompanied by a functional reduction in respiratory chain complexes I and III. These results offer a mechanism for the axonal degeneration observed in progressive MS patients. Because of the redistribution of Na + channels and the resulting increased influx of sodium, ATP consumption is greatly increased in demyelinated axons. 14, 15 To compensate for the higher energy demand, mitochondria migrate to the demyelinated axoplasm but have decreased respiratory capacity as found from the mRNA, protein, and functional data. The combination of an axon with increased energy demands and a mitochondrial population less able to meet those demands may therefore trigger premature axonal degeneration. This imbalance in energy needs may be further compounded by the fact that, in addition to defects in the expression of nuclear-encoded protein and mRNA, neurons in progressive MS, irrespective of the location and pathology, harbor increased levels of mitochondrial DNA deletions. [16] [17] [18] These results suggest that neuronal and axonal mitochondria pathology is prominent in MS tissues and may play a critical role in neuronal degeneration and MS pathogenesis.
In contrast to the predicted deleterious effect of the gene changes in the oxidative phosphorylation pathway, the changes in the GABAergic inhibitory neurotransmission pathway may be beneficial. Reduced inhibitory innervations upregulate neuroprotective pathways in murine cortex. 19 Decreased expression of the GABAergic genes coupled with increased expression of neurotrophic genes could therefore be part of the endogenous defense mechanism mounted by the MS brain. In the same dataset, increased ciliary neurotrophic factor (CNTF) signaling was found in motor neurons from nonlesioned motor cortex. CNTF is an established neurotrophic factor that enhances neuronal survival during development and in disease. Translational and transcriptional products of CNTF-related genes were quantified and localized in control and MS cortices. 20 An active and functionally significant role for CNTF in MS patients is supported by the report that MS patients with CNTF-null mutations have an earlier disease onset and a more aggressive disease course. 21 The microarraybased expression profiling studies and downstream validations described here therefore provide important insights into the disease pathogenesis.
Gene expression studies in cortical lesions
Gene expression studies in cortical lesions have focused on mechanisms associated with either the formation of cortical lesions or remyelination. Classically, cortical lesions derived from autopsy studies have shown an absence of infiltrating inflammatory cells and no disruption of the blood-brain barrier. Recently, however, using biopsy materials from acute MS patients, inflammatory cortical lesions have been reported. 22 The pathogenic role of acute cortical lesions and the reasons they cannot be detected with routine magnetic resonance imaging (MRI) procedures are still to be ascertained.
Meningeal inflammation and B-cell-like follicles, increasingly appreciated as pathological features of MS, have sometimes been associated with cortical lesions. [23] [24] [25] The role of meningeal B-cells in cortical pathology was explored in one of the first gene expression studies using cortical lesions. 26 Comparing cortical and meningeal tissues isolated from six MS and eight control patients, significant increases in levels of immunoglobulin G (IgG) genes as well as IgG deposition were detected in the meningeal layers of MS brains. No genes were found to be different between lesioned and nonlesioned cortical samples, possibly because of the heterogeneity of the samples and/or batch effects interfering with the results. Despite the upregulation of IgG genes in the brains of MS patients, there was no corresponding upregulation of the genes for FcR, which bind to IgGs in white matter. 26 The authors concluded that the upregulation of IgG-related genes and not FcRs probably reflected increased secretion of IgG from plasma cells, rather than B-cell accumulation. 26 Although some reports have detected the presence of Epstein-Barr virus (EBV) in meningeal B-cells that correlate with cortical lesions, 27,28 using polymerase chain reaction (PCR) techniques on DNA isolated from brains of MS patients, no EBV sequences were detected. While there is a significant association between EBV and MS, the link between B-cell-like follicles infected by EBV and cortical lesions remains to be established. 29, 30 In a more recent study, the gene expression of one acute and two chronic active MS cortical lesions was compared to cortical samples from three patients with tuberculous meningitis (representing an inflammatory meningeal condition), three with Alzheimer's disease (representing a neurodegenerative condition), and three controls. 31 Despite the use of formalin-fixed tissue for RNA measurements (offering less optimal sample quality compared to freshfrozen tissues), the identified cortical gene changes were highly specific to MS. The comparison between the single acute cortical lesion and the remaining samples showed, among others, increased expression of immune-related genes, which supports the rationale for further investigation of these extremely rare autopsy cases with active cortical lesions. 22, 31 Comparing MS cortical tissues with all other samples (tuberculous meningitis, Alzheimer's disease, and control cortex), several key biological pathways that could play a role in cortical MS pathology were identified including cell death, DNA damage, regulation of transcription, cell survival, and axonal and synaptic biology. The biological category of oxidative damage was also identified and oxidized lipids were localized to apoptotic neurons. 31 The presence of apoptotic neurons has been previously described in cortical lesions 7 although the mechanisms that lead to neuronal death in MS still remain to be established.
The restoration of myelin, or remyelination, is among the best known neuroprotective strategies. 1, 32 It is a spontaneous process that occurs both in experimental models and brains. [33] [34] [35] [36] [37] [38] A recent study in MS brains found enhanced reparative capacity of cortical lesions compared to white matter lesions. 39 Direct comparison of remyelination in Type I (leukocortical) lesions found 86% greater remyelination in gray matter compared to white matter. Interestingly, this repair process appeared to be ongoing, as the number of actively-myelinating oligodendrocytes (oligodendrocytes within cortical lesions with proteolipid protein (PLP)positive cell bodies and processes extending to short internodes) in the cortex was six times greater than in white matter. 39 Increases in hyaluronan and associated molecules have been shown to inhibit maturation of oligodendrocyte progenitor cells and remyelination. [38] [39] To analyze the difference in this propensity for remyelination, mRNA and protein levels of glial fibrillary acidic protein (GFAP), CD44, and versican (a hyaluronan-binding protein) were measured. Increases in mRNA and protein levels were detected in the white matter portion of leukocortical lesions compared to cortical portions. These findings suggest that cortical lesions have a more conducive environment for repair and remyelination. 38, 39 Simultaneous analysis of cortical and white matter tissue could therefore reveal important regulators of remyelination in MS. In one such comparison, PCR-based screening of 92 phosphotyrosine phosphatase mRNAs revealed DUSPY15/VHY as an inhibitor of oligodendrocyte maturation, 40 which is increased in MS lesions compared to controls. These studies support the utility of unbiased expression profiling as a reliable tool to understand molecular changes underlying cortical pathology.
Gene expression studies in MS hippocampus
The hippocampus is among the non-neocortical regions that are extensively demyelinated in progressive MS. [41] [42] [43] Cognitive dysfunction occurs in greater than 50% of MS patients, affecting episodic learning and memory, information processing speed, and working memory. Imaging and pathological studies support the possibility that hippocampal demyelination contributes to cognitive decline in MS patients. 44, 45 Hippocampal demyelination is a prominent feature of post-mortem MS brains, with 50%-80% of hippocampi showing some degree of demyelination. 42, 43 In our analysis, 12 of the 22 hippocampi analyzed were significantly demyelinated. 43 An encouraging observation was the retention of 80% or more of neurons in demyelinated hippocampi. This identifies the demyelinated hippocampal neuron as a promising therapeutic target. Despite the minimal neuronal loss, demyelinated hippocampi had a 40% decrease in synaptic densities and decreased expression of neuronal mRNA and proteins associated with axonal transport, glutamate neurotransmission, glutamate homeostasis, and memory and learning. 43 These data support the concept that demyelination alters neuronal gene expression and synaptic connectivity. 43 If reduced synaptic densities are a general consequence of demyelination, it could contribute to cortical atrophy and to the continuous neurological decline seen in the progressive stages of MS. Memory function was also impaired in an animal model of hippocampal demyelination, 46 with the majority of gene changes similar to those measured in MS demyelinated hippocampus. In addition, gene regulatory microRNAs have been identified in MS and rodent hippocampus that were shown to target altered genes and change their mRNA expression following demyelination. 46 The results support the hypothesis that microRNAs may alter neuronal gene function following demyelination. Using the rodent model of hippocampal demyelination, it was shown that remyelination abolished the memory dysfunction caused by demyelination. 46 Mechanistic insight into regulatory function of these microRNAs could lead to the development of therapeutic options targeted to enhancing neuronal function.
Conclusions
The genetic complexity of MS provides an ideal platform for the application of gene expression profiling studies. The few gene-related studies using cortical tissues from MS brains provide evidence of mitochondrial and oxidative damage, impaired axonal transport, synaptic dysfunction, impaired neurotransmission, and increased cell death pathways in MS cortical neurons. Additionally, generelated studies have also identified and validated increased neuroprotective pathways and remyelination efficiency in cortical lesions. This technology should now be applied specifically to compare pathological changes between normal and demyelinated cortex as well as between the relapsing-remitting and progressive disease courses. This is of paramount importance since the underlying mechanisms of cortical demyelination and associated changes are currently unknown. Cortical changes may also be retrogradely influenced by alterations in the spinal cord. Comparative gene changes in spinal cord coupled with proteomic approaches would therefore provide critical clues to disease progression and how downstream changes affect cortical pathology. Advances in newer RNA sequencing studies to determine gene changes have also been applied to MS research. 47 These tools should now be applied to determine RNA changes in MS cortical neurons. Recognizing the limitations of any technology is important for successful implementation. Microarray data therefore need to be validated using independent methods, preferably in independent cohorts of samples, to reconfirm the results. Investigators should avoid experiments lacking downstream validation, or using unsuitable or inadequately characterized biological material. Once quality control measures are followed, studies can be reliably compared between laboratories. Human tissue is not amenable to manipulation, thus efforts should be directed toward the development of animal models that mimic the cortical pathology observed in MS patients. Future research into regulatory factors such as transcription factors, microRNAs and epigenetic modifications that control gene expression in MS should also be undertaken. Finally, integration of pathology, neuroimaging, and genomic research will be critical in having a comprehensive understanding of the cortical pathology in MS.
